ClinicalTrials.gov
ClinicalTrials.gov Menu

Optical Tomographic Imaging of Infantile Hemangiomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01673971
Recruitment Status : Completed
First Posted : August 28, 2012
Last Update Posted : August 6, 2018
Sponsor:
Information provided by (Responsible Party):
Maria Garzon, Columbia University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The investigators hypothesize that there are differences between infantile hemangiomas (IH) during the proliferating and involuting phases and in response to medical treatment that can be detected by optical tomography of these hemangiomas.

Condition or disease
Infantile Hemangioma

Detailed Description:

Infantile hemangiomas (IH) are common vascular growths that frequently arise in infants. The clinical presentation is variable, and some hemangiomas have the potential to cause disfiguring and even lifethreatening complications. While there is no FDA approved treatment for IH, certain medications have been shown to be effective in shrinking the growths. Unfortunately, there is no objective tool to monitor IH or to guide treatment. Such a tool would improve the management of these patients. A new handheld wireless device uses diffuse optical imaging (DOI) technology to measure blood flow characteristics.

The device has been used in studies to assess patients with breast cancer. Optical tomography has also been increasingly used to assess neurological function and pathology in newborn infants.

The goal of the investigators' study is to assess the utility of DOI for characterizing and monitoring IH. Fifteen IH will be assessed at three points in time as part of this study, comprising two groups: 'Natural History' and 'Treatment'. DOI measurements will be correlated with clinical findings and existing ultrasound measurements of the IH.


Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Actual Enrollment : 15 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: Optical Tomographic Imaging of Infantile Hemangiomas
Study Start Date : May 2012
Actual Primary Completion Date : January 1, 2018
Actual Study Completion Date : January 1, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Birthmarks

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Natural History
Treatment


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Difference in absolute total hemoglobin concentration ([THb]) of hemangioma and normal skin. [ Time Frame: Up to 2 years ]
    Measurements of absolute total hemoglobin concentration ([THb]) of hemangioma and normal skin are obtained using a diffuse optical imaging device and are compared at different time points.

  2. Difference in tissue oxygen saturation (StO2) of hemangioma and normal skin. [ Time Frame: Up to 2 years ]
    Measurements of tissue oxygen saturation (StO2) of hemangioma and normal skin are obtained using a diffuse optical imaging device and are compared at different time points.


Secondary Outcome Measures :
  1. Difference in absolute total hemoglobin concentration ([THb]) of hemangioma at different time points. [ Time Frame: Up to 2 years ]
    Measurements of absolute total hemoglobin concentration ([THb]) of the hemangioma are obtained at different time points and compared.

  2. Difference in tissue oxygen saturation (StO2) of the hemangioma at different time points. [ Time Frame: Up to 2 years ]
    Measurements of tissue oxygen saturation (StO2) of the hemangioma are obtained at different time points and compared.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 7 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All subjects will be recruited verbally from the pediatric dermatology faculty practices, clinics and inpatient services at CUMC/NYP (MSCHONY). In accordance with CUMC policy, researchers will not approach a patient for recruitment until that patient has been informed of the study by their treating physician who has ascertained the patient's willingness to discuss the study with the investigators.
Criteria

For the 'Natural History' Cohort, the following inclusion and exclusion criteria apply:

INCLUSION CRITERIA:

  • Infants with IH who present to our practices within the first 2 months of life.
  • IH of size > 2 cm in diameter
  • IH located on area of skin that is accessible to contact by 4x2cm probe. Examples include the lateral face, forehead, scalp, trunk and areas of the extremities not overlying joints.

Infants with IH that do not necessitate either medical or surgical intervention at time of presentation.

EXCLUSION CRITERIA:

  • IH of size <2 cm in diameter
  • Complicated IH requiring medical or surgical intervention
  • IH located within 2 cm of the eye

For the 'Treatment' Cohort, the following inclusion and exclusion criteria apply:

INCLUSION CRITERIA:

  • Infants with IH who present to our practices within the first 2 months of life.
  • IH of size >2 cm in diameter
  • IH located on area of skin that is accessible to contact by 4x2cm probe. Examples include the lateral face, forehead,scalp, trunk and areas of the extremities not overlying joints.
  • IH that necessitate medical intervention with either oral or topical betablockers.

EXCLUSION CRITERIA:

  • IH <2 cm in size
  • Complicated IH requiring surgical intervention
  • IH located within 2 cm of the eye
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01673971


Locations
United States, New York
Columbia University Medical Center / Department of Dermatology
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
Investigators
Principal Investigator: Maria Garzon, MD Columbia University
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Maria Garzon, Professor of Clinical Dermatology and Clinical Pediatrics, Columbia University
ClinicalTrials.gov Identifier: NCT01673971     History of Changes
Other Study ID Numbers: AAAJ1201
First Posted: August 28, 2012    Key Record Dates
Last Update Posted: August 6, 2018
Last Verified: August 2018

Keywords provided by Maria Garzon, Columbia University:
hemangioma

Additional relevant MeSH terms:
Hemangioma
Hemangioma, Capillary
Port-Wine Stain
Neoplasms, Vascular Tissue
Neoplasms by Histologic Type
 Neoplasms
Skin Abnormalities
Congenital Abnormalities
Skin Diseases